Primary Biliary Cholangitis clinical trials at UC Health
1 research study open to eligible people
Primary Biliary Cholangitis with incomplete response or intolerant to ursodeoxycholic acid? Participate in a clinical trial
“Help us evaluate if a new investigational drug is safe and effective in the treatment of PBC”
open to eligible people ages 18-75
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
at UC Davis
Last updated: